Prognostic significance and clinicopathological associations of COX-2 SNP in patients with nonsmall cell lung cancer

Journal of Oncology

Volumn , Issue , 2009, Pages

  Brabender, Jan ^a   Grimminger, Peter P ^a   Sthlmacher, Jan ^b   Vallbhmer, Daniel ^a   Schneider, Paul M ^c   Hlscher, Arnulf H ^a   Metzger, Ralf ^a   Danenberg, Peter V ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MOLECULAR MARKER;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 73549119021     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/139590     Document Type: Article

References (48)

1. Hecht S. S., Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention Lancet Oncology 2002 3 8 461 469
2. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002 CA: A Cancer Journal for Clinicians 2005 55 2 74 108
3. American Cancer Society, Cancer Facts Figures 2008. American Cancer Society, Atlanta, Ga, USA, 2008
4. Coussens L. M., Werb Z., Inflammation and cancer Nature 2002 420 6917 860 867
5. Siemes C., Visser L. E., Coebergh J. W. W., Hofman A., Uitterlinden A. G., Stricker B. H. C., Protective effect of NSAIDs on cancer and influence of COX-2 C-765G genotype Current Cancer Drug Targets 2008 8 8 753 764
6. Jacobs E. J., Thun M. J., Bain E. B., Rodriguez C., Henley S. J., Calle E. E., A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence Journal of the National Cancer Institute 2007 99 8 608 615
7. Thun M. J., Namboodiri M. M., Heath C. W. Jr., Aspirin use and reduced risk of fatal colon cancer The New England Journal of Medicine 1991 325 23 1593 1596
8. Harris R. E., Beebe-Donk J., Doss H., Burr Doss D., Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review) Oncology Reports 2005 13 4 559 583
9. Vane J. R., Bakhle Y. S., Botting R. M., Cyclooxygenases 1 and 2 Annual Review of Pharmacology and Toxicology 1998 38 97 120
10. Vane J. R., Botting R. M., Mechanism of action of aspirin-like drugs Seminars in Arthritis and Rheumatism 1997 26 6, supplement 2 2 10
11. Koki A., Khan N. K., Woerner B. M., Cyclooxygenase-2 in human pathological disease Advances in Experimental Medicine and Biology 2002 507 177 184
12. Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S., Dubois R. N., Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 1994 107 4 1183 1188
13. Sano H., Kawahito Y., Wilder R. L., Expression of cyclooxygenase-1 and -2 in human colorectal cancer Cancer Research 1995 55 17 3785 3789
14. Tucker O. N., Dannenberg A. J., Yang E. K., Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer Cancer Research 1999 59 5 987 990
15. Hwang D., Scollard D., Byrne J., Levine E., Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer Journal of the National Cancer Institute 1998 90 6 455 460
16. Zimmermann K. C., Sarbia M., Weber A.-A., Borchard F., Gabbert H. E., Schror K., Cyclooxygenase-2 expression in human esophageal carcinoma Cancer Research 1999 59 1 198 204
17. Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M., Expression of cyclooxygenase-2 in human gastric carcinoma Cancer Research 1997 57 7 1276 1280
18. Soslow R. A., Dannenberg A. J., Rush D., COX-2 is expressed in human pulmonary, colonic, and mammary tumors Cancer 2000 89 12 2637 2645
19. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A., Expression of cyclooxygenase-2 in human lung carcinoma Cancer Research 1998 58 22 4997 5001
20. Uotila P., Valve E., Martikainen P., Nevalainen M., Nurmi M., Harkonen P., Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer Urological Research 2001 29 1 25 28
21. Kulkarni S., Rader J. S., Zhang F., Cyclooxygenase-2 is overexpressed in human cervical cancer Clinical Cancer Research 2001 7 2 429 434
22. Shirahama T., Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder Clinical Cancer Research 2000 6 6 2424 2430
23. Tong B. J., Tan J., Tajeda L., Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta human endometrial adenocarcinoma Neoplasia 2000 2 6 483 490
24. Goekkurt E., Hoehn S., Wolschke C., Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)novel predictors for response and survival in gastric cancer patients British Journal of Cancer 2006 94 2 281 286
25. Marcuello E., Altes A., del Rio E., Cesar A., Menoyo A., Baiget M., Single nucleotide polymorphism in the 5′ tandem repeat sequences of Thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients International Journal of Cancer 2004 112 5 733 737
26. Cohen V., Panet-Raymond V., Sabbaghian N., Morin I., Batist G., Rozen R., Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy Clinical Cancer Research 2003 9 5 1611 1615
27. Stoehlmacher J., Park D. J., Zhang W., A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer British Journal of Cancer 2004 91 2 344 354
28. Zhou W., Gurubhagavatula S., Liu G., Excision repair cross- complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy Clinical Cancer Research 2004 10 15 4939 4943
29. Pan J.-H., Han J.-X., Wu J.-M., Sheng L.-J., Huang H.-N., Yu Q.-Z., MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer Respiration 2008 75 4 380 385
30. Papafili A., Hill M. R., Brull D. J., Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 10 1631 1636
31. Campa D., Zienolddiny S., Maggini V., Skaug V., Haugen A., Canzian F., Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer Carcinogenesis 2004 25 2 229 235 (Pubitemid 38239806)
32. Schneider P. M., Praeuer H. W., Stoeltzing O., Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer British Journal of Cancer 2000 83 4 473 479
33. Mountain C. F., Revisions in the international system for staging lung cancer Chest 1997 111 6 1710 1717
34. Miller R., Siegmund D., Maximally selected chi square statistics Biometrics 1982 38 4 1011 1016
35. Kaplan E., Meier P., Nonparametric estimation from incomplete observations The Journal of the American Medical Association 1958 53 457 481
36. Dannenberg A. J., Subbaramaiah K., Targeting cyclooxygenase-2 in human neoplasia: rationale and promise Cancer Cell 2003 4 6 431 436
37. Dandekar D. S., Lokeshwar B. L., Inhibition of cyclooxygenase (COX)-2 expression by tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs Clinical Cancer Research 2004 10 23 8037 8047
38. Kishi K., Petersen S., Petersen C., Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor Cancer Research 2000 60 5 1326 1331 (Pubitemid 30152002)
39. Oshima M., Dinchuk J. E., Kargman S. L., Suppression of intestinal polyposis in Apc(delta716) knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 1996 87 5 803 809
40. Khuri F. R., Wu H., Lee J. J., Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer Clinical Cancer Research 2001 7 4 861 867
41. Yuan A., Yu C.-J., Shun C.-T., Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients International Journal of Cancer 2005 115 4 545 555
42. Brabender J., Park J., Metzger R., Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer Annals of Surgery 2002 235 3 440 443 (Pubitemid 34183896)
43. Ristimaki A., Sivula A., Lundin J., Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer Cancer Research 2002 62 3 632 635
44. Gallo O., Masini E., Bianchi B., Bruschini L., Paglierani M., Franchi A., Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma Human Pathology 2002 33 7 708 714
45. Konno H., Baba M., Shoji T., Ohta M., Suzuki S., Nakamura S., Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer Clinical and Experimental Metastasis 2002 19 6 527 534
46. Ferrandina G., Lauriola L., Zannoni G. F., Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications British Journal of Cancer 2002 87 10 1145 1152
47. Li F., Ren G. S., Li H. Y., Wang X. Y., Chen L., Li J., A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer Clinical Oncology 2009 21 4 302 305
48. Shen J., Gammon M. D., Terry M. B., Teitelbaum S. L., Neugut A. I., Santella R. M., Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk Breast Cancer Research 2006 8 6, article R71